Mandate

Vinge advises Biotage in connection with its acquisition of PhyNexus

December 06, 2018 Capital Markets and Public M&A

Vinge advises Biotage AB (publ) (“Biotage”), listed on Nasdaq Stockholm, in connection with its acquisition of PhyNexus, Inc. (“PhyNexus”), financed through a combination of newly issued shares and existing cash at hand.


The transaction is expected to be completed in January 2019 and is subject to customary closing conditions.

Biotage offers efficient separation technologies from analysis to industrial-scale and high-quality solutions for analytical chemistry from research to commercial analysis laboratories. The company is headquartered in Uppsala and has offices in the US, UK, China, Japan, South Korea and India. Biotage has approx. 410 employees and had sales of 748 MSEK in 2017.

Vinge’s team consists of Dain Hård Nevonen, Malte Hedlund and Josephine Andersson. 

Related

Vinge advises FAM AB on the acquisition of Aktiebolaget Näckström

Vinge has advised FAM AB on its acquisition of Aktiebolaget Näckström from Vectura Fastigheter AB. The principal assets of Aktiebolaget Näckström comprise the property Stockholm Näckström 6 (Arsenalsgatan 8) and Villa Täcka udden.
October 16, 2025

Vinge has advised FAM in connection with its investment in GreenIron

Vinge has advised FAM AB, owned by the Wallenberg Foundations, in connection with its investment in GreenIron H2 AB. Through the round, GreenIron raised in total SEK 125 million in additional funding from existing shareholders, with FAM now becoming the company’s largest owner.
October 16, 2025

Vinge has advised on the sale of Westcomp AB to Tången Industrikapital AB

Pursuant to the transaction, Tången acquires approximately 91 per cent of the shares in Westcomp.
October 15, 2025